Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability

World Journal of Surgery

Volumn 34, Issue 9, 2010, Pages 2090-2097

  Sjölund, Katarina ^a   Andersson, Anna ^a   Nilsson, Erik ^a   Nilsson, Ola ^a   Ahlman, Håkan ^a   Nilsson, Bengt ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SUNITINIB;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG ANTAGONISM; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; GENETICS; HUMAN; MALE; MIDDLE AGED; MISSENSE MUTATION; MORTALITY; NUCLEOTIDE SEQUENCE; RADIOGRAPHY; SURVIVAL;

AGED; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MALE; MIDDLE AGED; MUTATION, MISSENSE; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES; SEQUENCE DELETION; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79952109599     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-010-0639-5     Document Type: Article

References (27)

1. DeMatteo RP, Heinrich MC, El-Rifai WM et al (2002) Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 33:466-477
2. Tuveson DA, Willis NA, Jacks T et al (2001) STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20:5054-5058
3. Blay JY, Bonvalot S, Casali P et al (2005) Consensus meeting for the management of gastrointestinal stromal tumours: report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 16:566-578
4. Nilsson B, Andersson A, Ahlman H (2008) Adjuvant and downstaging treatment with imatinib in gastrointestinal stromal tumors. J Surg Oncol 98:145-146
5. Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337
6. Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349
7. Corless CL, Schroeder A, Griffith D et al (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23:5357-5364
8. Prenen H, Cools J, Mentens N et al (2006) Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12:2622-2627
9. Debiec-Rychter M, Sciot R, Le Cesne A et al (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42: 1093-1103
10. Lasota J, Miettinen M (2008) Clinical significance of oncogenic KIT or PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 53:245-266
11. Liegl B, Hornick JL, Corless CL et al (2008) Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol 33:437-446
12. Eisenberg BL, Harris J, Blanke CD et al (2009) Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 99:42-47
13. Fletcher CD, Berman JJ, Corless C et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459-465
14. Nilsson B, Bümming P, Meis-Kindblom JM et al (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 103:821-829
15. Andersson J, Bumming P, Meis-Kindblom JM et al (2006) Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 130:1573-1581
16. Lo SS, Papacristou GI, Finkelstein SD et al (2005) Neoadjuvant imatinib in gastrointestinal stromal tumour of the rectum: report of a case. Dis Colon Rectum 48:1316-1319
17. Ludvigsen L, Toxvaerd A, Mahdi B et al (2007) Successful resection of an advanced duodenal gastrointestinal stromal tumor after downstaging with Imatinib: report of a case. Surg Today 37:1105-1109
18. Haller F, Detken S, Schulten HJ et al (2007) Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol 14:526-532
19. Loughrey MB, Mitchell C, Mann GB et al (2005) Gastrointestinal stromal tumour treated with neoadjuvant imatinib. J Clin Pathol 58:779-781
20. Van Glabbeke M, Verweij J, Casali PG et al (2005) Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials group study. J Clin Oncol 23:5795-5804
21. Bümming P, Andersson J, Meis-Kindblom JM et al (2003) Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a center based study of 17 patients. Br J Cancer 89:460-464
22. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-896
23. Ruka W, Rutkowski P, Szawlowski A et al (2008) Surgical resection of residual disease in initially inoperable imatinibresistant/intolerant gastrointestinal stromal tumor treated with sunitinib. Eur J Surg Oncol 35:87-91
24. Hohenberger P, Oladeji O, Licht A, et al. (2009) Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). J Clin Oncol 27(Suppl):15 s (abstract 10550)
25. McAuliffe J, Hunt K, Lazar A et al (2009) A randomized phase II study of preoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 16:910-919
26. Gold J, DeMatteo R (2006) Neoadjuvant therapy for gastrointestinal stromal tumor (GIST): racing against resistance. Ann Surg Oncol 14:1247-1248
27. Blanke C, Demetri G, von Mehren M et al (2008) Long term results from a phase II trial of standard-versus higher dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620-625